Balancing the risks of Tysabri dosing holidays

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Balancing the risks of Tysabri dosing holidays

Postby MSUK » Sun Sep 19, 2010 11:57 pm

Image

A new study may help clinicians balance the risks and potential benefits of suspending natalizumab dosing in patients with relapsing multiple sclerosis (MS), according to research presented here at the 135th Annual Meeting of the American Neurological Association (ANA).

There is no clear answer, said Timothy West, MD, University of California San Francisco (UCSF) Multiple Sclerosis Center, San Francisco, California, on September 15. Continuing dosing appears to increase the risk for developing progressive multifocal leucoencephalopathy (PML). Suspending dosing to reduce the risk of PML may contribute to an increased risk for MS flares.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2184
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service